Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis
This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT). This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT an...
Saved in:
| Published in | Surgical oncology Vol. 28; pp. 228 - 235 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
01.03.2019
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0960-7404 1879-3320 1879-3320 |
| DOI | 10.1016/j.suronc.2019.01.006 |
Cover
Loading…
| Abstract | This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT).
This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients’ demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity.
After matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS.
TACE + SBRT is safe and results in better survivals in nonresectable HCC patients. |
|---|---|
| AbstractList | BackgroundThis study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT).MethodsThis was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients’ demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity.ResultsAfter matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS.ConclusionTACE + SBRT is safe and results in better survivals in nonresectable HCC patients. This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT).BACKGROUNDThis study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT).This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients' demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity.METHODSThis was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients' demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity.After matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS.RESULTSAfter matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS.TACE + SBRT is safe and results in better survivals in nonresectable HCC patients.CONCLUSIONTACE + SBRT is safe and results in better survivals in nonresectable HCC patients. This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT). This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients' demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity. After matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS. TACE + SBRT is safe and results in better survivals in nonresectable HCC patients. |
| Author | Ho, Connie HM Dai, Wing-Chiu Luk, Mai-Yee Leung, To-Wai Yeung, Cynthia SY Wong, Frank CS Wong, Tiffany CL Chan, Albert CY Lee, Victor HF Lee, Ann-Shing Lo, Chung-Mau Cheung, Tan-To Chiang, Chi-Leung Ng, Kelvin KC Chok, Siu-Ho |
| Author_xml | – sequence: 1 givenname: Tiffany CL orcidid: 0000-0002-3142-7678 surname: Wong fullname: Wong, Tiffany CL organization: Department of Surgery, The University of Hong Kong, Hong Kong – sequence: 2 givenname: Chi-Leung surname: Chiang fullname: Chiang, Chi-Leung organization: Department of Clinical Oncology, The University of Hong Kong, Hong Kong – sequence: 3 givenname: Ann-Shing surname: Lee fullname: Lee, Ann-Shing organization: Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong – sequence: 4 givenname: Victor HF surname: Lee fullname: Lee, Victor HF organization: Department of Clinical Oncology, The University of Hong Kong, Hong Kong – sequence: 5 givenname: Cynthia SY surname: Yeung fullname: Yeung, Cynthia SY organization: Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong – sequence: 6 givenname: Connie HM surname: Ho fullname: Ho, Connie HM organization: Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong – sequence: 7 givenname: Tan-To surname: Cheung fullname: Cheung, Tan-To organization: Department of Surgery, The University of Hong Kong, Hong Kong – sequence: 8 givenname: Kelvin KC surname: Ng fullname: Ng, Kelvin KC organization: Department of Surgery, The University of Hong Kong, Hong Kong – sequence: 9 givenname: Siu-Ho surname: Chok fullname: Chok, Siu-Ho organization: Department of Surgery, The University of Hong Kong, Hong Kong – sequence: 10 givenname: Albert CY surname: Chan fullname: Chan, Albert CY organization: Department of Surgery, The University of Hong Kong, Hong Kong – sequence: 11 givenname: Wing-Chiu surname: Dai fullname: Dai, Wing-Chiu organization: Department of Surgery, The University of Hong Kong, Hong Kong – sequence: 12 givenname: Frank CS surname: Wong fullname: Wong, Frank CS organization: Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong – sequence: 13 givenname: Mai-Yee orcidid: 0000-0003-2409-6150 surname: Luk fullname: Luk, Mai-Yee organization: Department of Clinical Oncology, The University of Hong Kong, Hong Kong – sequence: 14 givenname: To-Wai surname: Leung fullname: Leung, To-Wai organization: Department of Clinical Oncology, The University of Hong Kong, Hong Kong – sequence: 15 givenname: Chung-Mau surname: Lo fullname: Lo, Chung-Mau email: chungmlo@hku.hk organization: Department of Surgery, The University of Hong Kong, Hong Kong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30851906$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc2KFDEUhQsZcXpG30Ak4MZNtTf1X4MI4-AfDLjRdbiVumWnTSVtkmopH8snNN01s-lNbxIufOdwOOcquTDWUJK85LDmwKu327WfnDVynQFv18DXANWTZMWbuk3zPIOLZAVtBWldQHGZXHm_hUjUGX-WXObQlLyFapX8-0AhkGPRa6_2qBkOxzM-ZAPKoCTrbD8zh73CoKxhYUMOdzMbrNb2jzI_WXBoPLqoUdFBbmi0NHZWq7-LQhkWwzvyJAN2mtiGdhisJK0njY5JdFIZO-INu2U7Z3dkvAoz89I6YiOGaNkzNKhnr_zz5OmA2tOLh_86-fHp4_e7L-n9t89f727vU1lCG9K-wqKUAw7YUUd5k8m8jkdRt7ItSyhlnQ2QFSXWzZBBDW2ZNU1XDw0vhibLIb9O3iy-MdHviXwQo_KHzGjITl5ksUFo24q3EX19gm7t5GLeSC1dF3kTqVcP1NSN1IudUyO6WTyuEYGbBZDOeu9oEFKFY4WxYaUFB3GYXmzFMr04TC-ACziKixPxo_8Z2ftFRrHKvSInvFRkJPXKxblEb9U5g3cnBlIroyTqXzSfl_8HG4zkeQ |
| CitedBy_id | crossref_primary_10_1016_j_ejso_2024_109502 crossref_primary_10_1016_j_bpg_2020_101709 crossref_primary_10_3748_wjg_v27_i24_3630 crossref_primary_10_1002_prm2_12033 crossref_primary_10_1016_j_hbpd_2024_09_005 crossref_primary_10_1016_S2468_1253_22_00339_9 crossref_primary_10_3390_cancers15245749 crossref_primary_10_1055_s_0044_1791837 crossref_primary_10_3390_cancers12102955 crossref_primary_10_1016_j_ctro_2023_100627 crossref_primary_10_1016_j_jncc_2022_05_002 crossref_primary_10_12998_wjcc_v8_i13_2758 crossref_primary_10_3350_cmh_2022_0399 crossref_primary_10_1016_j_jceh_2025_102505 crossref_primary_10_2147_JHC_S284403 crossref_primary_10_2147_JHC_S285735 crossref_primary_10_14218_JCTH_2020_00188 crossref_primary_10_3389_fonc_2019_01157 crossref_primary_10_3389_fonc_2021_640461 crossref_primary_10_1002_jcb_29404 crossref_primary_10_1002_hep_31992 crossref_primary_10_2139_ssrn_3858818 crossref_primary_10_1016_j_ijrobp_2023_09_047 crossref_primary_10_1007_s00432_020_03389_2 |
| Cites_doi | 10.1186/s12885-016-2894-9 10.1038/nrclinonc.2016.211 10.1055/s-0030-1247133 10.1371/journal.pone.0072306 10.1111/hpb.12331 10.1016/S0140-6736(17)31046-2 10.1016/j.semradonc.2005.04.005 10.1016/j.ajo.2009.08.024 10.1007/s00270-009-9711-7 10.1053/jhep.2003.50047 10.1016/j.surg.2016.05.045 10.1016/j.jhep.2013.02.022 10.1016/S0140-6736(02)08649-X 10.1007/s12094-010-0492-x 10.1200/JCO.2012.44.1659 10.1007/s12072-010-9165-7 10.1038/nrclinonc.2014.122 10.1093/jjco/hyq123 10.1002/hep.24199 10.1016/j.ijrobp.2011.04.011 10.1055/s-0030-1247132 10.1016/j.ijrobp.2005.01.002 10.1016/S0360-3016(03)00434-6 10.1016/j.ijrobp.2017.01.221 10.1016/j.ijrobp.2017.09.001 10.1159/000327577 10.6004/jnccn.2017.0059 10.1200/JCO.2017.76.2229 10.1111/liv.12314 10.1007/s00066-015-0929-9 10.1016/S1470-2045(18)30351-6 10.1038/nrdp.2016.18 10.1002/cncr.27533 10.1111/j.1478-3231.2005.01170.x 10.1002/jso.24518 10.1053/jhep.2002.33156 10.1097/SLA.0b013e3182111195 10.1002/cncr.30008 10.1016/j.ijrobp.2015.07.984 10.1080/14712598.2018.1499722 |
| ContentType | Journal Article |
| Copyright | 2019 Copyright © 2019. Published by Elsevier Ltd. Copyright Elsevier Limited Mar 2019 |
| Copyright_xml | – notice: 2019 – notice: Copyright © 2019. Published by Elsevier Ltd. – notice: Copyright Elsevier Limited Mar 2019 |
| DBID | AAYXX CITATION NPM 7QO 8FD FR3 K9. P64 7X8 |
| DOI | 10.1016/j.suronc.2019.01.006 |
| DatabaseName | CrossRef PubMed Biotechnology Research Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-3320 |
| EndPage | 235 |
| ExternalDocumentID | 30851906 10_1016_j_suronc_2019_01_006 S0960740418303839 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 4.4 457 4CK 4G. 53G 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACIWK ACPRK ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AEVXI AFJKZ AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ SV3 T5K UDS UHS WH7 WUQ Z5R ~G- 3V. 7X7 8FI AACTN AAIAV ABLVK ABYKQ AFCTW AFKRA AFKWA AJBFU AJOXV AMFUW AZQEC BENPR EFLBG FYUFA GUQSH LCYCR M1P M2O RIG AAYXX AGRNS CITATION NPM 7QO 8FD FR3 K9. P64 7X8 |
| ID | FETCH-LOGICAL-c509t-d6a45cfafabebe382c37afa479c95505c72f0245a78f207095288b7f814f82303 |
| IEDL.DBID | .~1 |
| ISSN | 0960-7404 1879-3320 |
| IngestDate | Thu Jul 10 19:35:49 EDT 2025 Sat Jul 26 02:26:44 EDT 2025 Thu Apr 03 07:09:29 EDT 2025 Tue Jul 01 03:02:12 EDT 2025 Thu Apr 24 22:58:29 EDT 2025 Fri Feb 23 02:28:19 EST 2024 Tue Aug 26 16:32:21 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Unresectable Hepatocellular carcinoma Stereotactic body radiation therapy Transarterial chemoembolization Outcomes |
| Language | English |
| License | Copyright © 2019. Published by Elsevier Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c509t-d6a45cfafabebe382c37afa479c95505c72f0245a78f207095288b7f814f82303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2409-6150 0000-0002-3142-7678 |
| PMID | 30851906 |
| PQID | 2308519438 |
| PQPubID | 1216388 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2190099619 proquest_journals_2308519438 pubmed_primary_30851906 crossref_citationtrail_10_1016_j_suronc_2019_01_006 crossref_primary_10_1016_j_suronc_2019_01_006 elsevier_sciencedirect_doi_10_1016_j_suronc_2019_01_006 elsevier_clinicalkey_doi_10_1016_j_suronc_2019_01_006 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2019 2019-03-00 2019-Mar 20190301 |
| PublicationDateYYYYMMDD | 2019-03-01 |
| PublicationDate_xml | – month: 03 year: 2019 text: March 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Oxford |
| PublicationTitle | Surgical oncology |
| PublicationTitleAlternate | Surg Oncol |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Zeng, Lv, Mei (bib8) 2016 Velec, Haddad, Craig, Wang, Lindsay, Brierley (bib31) 2017; 97 Cárdenes, Price, Perkins, Maluccio, Kwo, Breen (bib10) 2010; 12 Yamada, Izaki, Sugimoto, Mayahara, Morita, Yoden (bib33) 2003; 57 Shim, Seong, Han, Chon, Suh, Lee (bib28) 2005; 25 Are, Meyer, Stack, Ahmad, Smith, Qian (bib3) 2017; 115 Llovet, Bruix (bib27) 2003; 37 Dawson, Ten Haken (bib32) 2005; 15 Kudo, Izumi, Kokudo, Matsui, Sakamoto, Nakashima (bib24) 2011; 29 Weichselbaum, Liang, Deng, Fu (bib40) 2017; 14 Sangro, Gomez-Martin, de la Mata, Inarrairaegui, Garralda, Barrera (bib39) 2013; 59 Lo, Ngan, Tso, Liu, Lam, Poon (bib4) 2002; 35 Forner, Reig, de Lope, Bruix (bib23) 2010; 30 Dow JM, Brock, Ten Haken, Balter, Lawerence, Feng (bib29) 2015; 93 Omata, Lesmana, Tateishi, Chen, Lin, Yoshida (bib25) 2010; 4 Yamada, Izaki, Sugimoto, Mayahara, Morita, Yoden (bib9) 2003; 57 Schefter, Kavanagh, Timmerman, Cardenes, Baron, Gaspar (bib30) 2005; 62 Sheetz, Derstine, Englesbe (bib21) 2016; 160 Radiation Therapy Oncology Group RTOG 1112 (bib42) Sapir, Tao, Schipper, Bazzi, Novelli, Devlin (bib22) 2018; 100 Llovet, Zucman-Rossi, Pikarsky, Sangro, Schwartz, Sherman (bib1) 2016; 2 Andolino, Johnson, Maluccio, Kwo, Tector, Zook (bib11) 2011; 81 Bujold, Massey, Kim, Brierley, Cho, Wong (bib13) 2013; 31 Benson, D'Angelica, Abbott, Abrams, Alberts, Saenz (bib26) 2017; 15 Takeda, Sanuki, Tsurugai, Iwabuchi, Matsunaga, Ebinuma (bib16) 2016; 122 Cheng, Amarapurkar, Chao, Chen, Geschwind, Goh (bib6) 2014; 34 Su, Lu, Cheng, Zhou, Huang, Gao (bib15) 2016; 16 Bruix, Sherman (bib18) 2011; 53 Rubin (bib20) 2010; 149 Chan, Lee, Chiang, Lee, Law, Sin (bib17) 2016; 192 Lammer, Malagari, Vogl, Pilleul, Denys, Watkinson (bib7) 2010; 33 Lencioni, Llovet (bib19) 2010; 30 Fung, Poon, Yu, Chan, Chan, Chok (bib35) 2013; 8 Llovet, Real, Montana, Planas, Coll, Aponte (bib5) 2002; 359 Zhu, Finn, Edeline, Cattan, Ogasawara, Palmer (bib38) 2018; 19 Fan, Lo, Poon, Yeung, Leung Liu, Yuen (bib34) 2011; 253 Forner, Gilabert, Bruix, Raoul (bib43) 2014; 11 Kudo, Han, Kokudo, Cheng, Choi, Furuse (bib2) 2010; 40 Luke, Lemons, Karrison, Pitroda, Melotek, Zha (bib41) 2018; 36 Kang, Kim, Cho, Yang, Yoo, Kim (bib12) 2012; 118 Waidmann (bib36) 2018; 18 El-Khoueiry, Sangro, Yau, Crocenzi, Kudo, Hsu (bib37) 2017; 389 Jacob, Turley, Redden, Saddekni, Aal, Keene (bib14) 2015; 17 Lo (10.1016/j.suronc.2019.01.006_bib4) 2002; 35 Zeng (10.1016/j.suronc.2019.01.006_bib8) 2016 Velec (10.1016/j.suronc.2019.01.006_bib31) 2017; 97 Omata (10.1016/j.suronc.2019.01.006_bib25) 2010; 4 Yamada (10.1016/j.suronc.2019.01.006_bib9) 2003; 57 Andolino (10.1016/j.suronc.2019.01.006_bib11) 2011; 81 Bujold (10.1016/j.suronc.2019.01.006_bib13) 2013; 31 Yamada (10.1016/j.suronc.2019.01.006_bib33) 2003; 57 Sapir (10.1016/j.suronc.2019.01.006_bib22) 2018; 100 Cheng (10.1016/j.suronc.2019.01.006_bib6) 2014; 34 Cárdenes (10.1016/j.suronc.2019.01.006_bib10) 2010; 12 Shim (10.1016/j.suronc.2019.01.006_bib28) 2005; 25 Bruix (10.1016/j.suronc.2019.01.006_bib18) 2011; 53 Lencioni (10.1016/j.suronc.2019.01.006_bib19) 2010; 30 Luke (10.1016/j.suronc.2019.01.006_bib41) 2018; 36 Su (10.1016/j.suronc.2019.01.006_bib15) 2016; 16 Benson (10.1016/j.suronc.2019.01.006_bib26) 2017; 15 Weichselbaum (10.1016/j.suronc.2019.01.006_bib40) 2017; 14 Kudo (10.1016/j.suronc.2019.01.006_bib2) 2010; 40 Forner (10.1016/j.suronc.2019.01.006_bib23) 2010; 30 Takeda (10.1016/j.suronc.2019.01.006_bib16) 2016; 122 Llovet (10.1016/j.suronc.2019.01.006_bib27) 2003; 37 Kudo (10.1016/j.suronc.2019.01.006_bib24) 2011; 29 Sangro (10.1016/j.suronc.2019.01.006_bib39) 2013; 59 Chan (10.1016/j.suronc.2019.01.006_bib17) 2016; 192 Are (10.1016/j.suronc.2019.01.006_bib3) 2017; 115 Llovet (10.1016/j.suronc.2019.01.006_bib5) 2002; 359 Sheetz (10.1016/j.suronc.2019.01.006_bib21) 2016; 160 Schefter (10.1016/j.suronc.2019.01.006_bib30) 2005; 62 Forner (10.1016/j.suronc.2019.01.006_bib43) 2014; 11 Kang (10.1016/j.suronc.2019.01.006_bib12) 2012; 118 Rubin (10.1016/j.suronc.2019.01.006_bib20) 2010; 149 Jacob (10.1016/j.suronc.2019.01.006_bib14) 2015; 17 Dow JM (10.1016/j.suronc.2019.01.006_bib29) 2015; 93 Fung (10.1016/j.suronc.2019.01.006_bib35) 2013; 8 Dawson (10.1016/j.suronc.2019.01.006_bib32) 2005; 15 Zhu (10.1016/j.suronc.2019.01.006_bib38) 2018; 19 Lammer (10.1016/j.suronc.2019.01.006_bib7) 2010; 33 El-Khoueiry (10.1016/j.suronc.2019.01.006_bib37) 2017; 389 Llovet (10.1016/j.suronc.2019.01.006_bib1) 2016; 2 Radiation Therapy Oncology Group RTOG 1112 (10.1016/j.suronc.2019.01.006_bib42) Fan (10.1016/j.suronc.2019.01.006_bib34) 2011; 253 Waidmann (10.1016/j.suronc.2019.01.006_bib36) 2018; 18 |
| References_xml | – volume: 57 start-page: 113 year: 2003 end-page: 119 ident: bib9 article-title: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 160 start-page: 1425 year: 2016 end-page: 1426 ident: bib21 article-title: Propensity scores for comparative effectiveness research: finding the right match publication-title: Surgery – volume: 15 start-page: 279 year: 2005 end-page: 283 ident: bib32 article-title: Partial volume tolerance of the liver to radiation publication-title: Semin. Radiat. Oncol. – volume: 93 start-page: E169 year: 2015 end-page: E170 ident: bib29 article-title: Potential benefits of fractionation over SBRT for large liver tumors publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 2 start-page: 16018 year: 2016 ident: bib1 article-title: Hepatocellular carcinoma publication-title: Nat. Rev. Dis. Prim. – volume: 192 start-page: 92 year: 2016 end-page: 101 ident: bib17 article-title: Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas publication-title: Strahlenther. Onkol. : Organ der Deutschen Rontgengesellschaft [et al] – volume: 97 start-page: 939 year: 2017 end-page: 946 ident: bib31 article-title: Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 30 start-page: 52 year: 2010 end-page: 60 ident: bib19 article-title: Modified RECIST(mRECIST) assessment for hepatocellular carcinoma publication-title: Semin. Liver Dis. – volume: 37 start-page: 429 year: 2003 end-page: 442 ident: bib27 article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival publication-title: Hepatology – volume: 15 start-page: 563 year: 2017 end-page: 573 ident: bib26 article-title: NCCN guidelines insights: hepatobiliary cancers, version 1.2017 publication-title: J. Natl. Compr. Canc. Netw. : JNCCN – volume: 59 start-page: 81 year: 2013 end-page: 88 ident: bib39 article-title: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C publication-title: J. Hepatol. – volume: 16 start-page: 834 year: 2016 ident: bib15 article-title: Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm publication-title: BMC Canc. – volume: 11 start-page: 525 year: 2014 end-page: 535 ident: bib43 article-title: Treatment of intermediate-stage hepatocellular carcinoma publication-title: Nat. Rev. Clin. Oncol. – volume: 40 start-page: i19 year: 2010 end-page: 27 ident: bib2 article-title: Liver cancer working group report publication-title: Jpn. J. Clin. Oncol. – volume: 30 start-page: 61 year: 2010 end-page: 74 ident: bib23 article-title: Current strategy for staging and treatment: the BCLC update and future prospects publication-title: Semin. Liver Dis. – volume: 17 start-page: 140 year: 2015 end-page: 149 ident: bib14 article-title: Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of >/= 3 cm publication-title: HPB (Oxford) – volume: 253 start-page: 745 year: 2011 end-page: 758 ident: bib34 article-title: Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience publication-title: Ann. Surg. – volume: 8 year: 2013 ident: bib35 article-title: Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome publication-title: PLoS One – volume: 118 start-page: 5424 year: 2012 end-page: 5431 ident: bib12 article-title: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization publication-title: Cancer – volume: 149 start-page: 7 year: 2010 end-page: 9 ident: bib20 article-title: Propensity score methods publication-title: Am. J. Ophthalmol. – volume: 122 start-page: 2041 year: 2016 end-page: 2049 ident: bib16 article-title: Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation publication-title: Cancer – volume: 12 start-page: 218 year: 2010 end-page: 225 ident: bib10 article-title: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma publication-title: Clin. Transl. Oncol. – volume: 53 start-page: 1020 year: 2011 end-page: 1022 ident: bib18 article-title: American association for the study of liver diseases. Management of hepatocellular carcinoma: an update publication-title: Hepatology – volume: 359 start-page: 1734 year: 2002 end-page: 1739 ident: bib5 article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial publication-title: Lancet – volume: 31 start-page: 1631 year: 2013 end-page: 1639 ident: bib13 article-title: Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma publication-title: J. Clin. Oncol. – volume: 35 start-page: 1164 year: 2002 end-page: 1171 ident: bib4 article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma publication-title: Hepatology – volume: 36 start-page: 1611 year: 2018 end-page: 1618 ident: bib41 article-title: Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors publication-title: J. Clin. Oncol. – volume: 100 start-page: 122 year: 2018 end-page: 130 ident: bib22 article-title: Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 34 start-page: 174 year: 2014 end-page: 183 ident: bib6 article-title: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel publication-title: Liver Int. : Offic. J. Int. Assoc. Stud. Liver – ident: bib42 article-title: Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma – volume: 4 start-page: 439 year: 2010 end-page: 474 ident: bib25 article-title: Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma publication-title: Hepatol. Int. – volume: 19 start-page: 940 year: 2018 end-page: 952 ident: bib38 article-title: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial publication-title: Lancet Oncol. – volume: 33 start-page: 41 year: 2010 end-page: 52 ident: bib7 article-title: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study publication-title: Cardiovasc. Interv. Radiol. – volume: 62 start-page: 1371 year: 2005 end-page: 1378 ident: bib30 article-title: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 25 start-page: 1189 year: 2005 end-page: 1196 ident: bib28 article-title: Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma publication-title: Liver Int. : Offic. J. Int. Assoc. Stud. Liver – year: 2016 ident: bib8 article-title: Efficacy and Safety of Transarterial Chemoembolization Plus Sorafenib for Early or Intermediate Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinics and Research in Hepatology and Gastroenterology – volume: 389 start-page: 2492 year: 2017 end-page: 2502 ident: bib37 article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial publication-title: Lancet – volume: 18 start-page: 905 year: 2018 end-page: 910 ident: bib36 article-title: Recent developments with immunotherapy for hepatocellular carcinoma publication-title: Expert Opin. Biol. Ther. – volume: 115 start-page: 591 year: 2017 end-page: 602 ident: bib3 article-title: Global trends in the burden of liver cancer publication-title: J. Surg. Oncol. – volume: 81 start-page: e447 year: 2011 end-page: e453 ident: bib11 article-title: Stereotactic body radiotherapy for primary hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 29 start-page: 339 year: 2011 end-page: 364 ident: bib24 article-title: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version publication-title: Dig. Dis. – volume: 57 start-page: 113 year: 2003 end-page: 119 ident: bib33 article-title: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 14 start-page: 365 year: 2017 end-page: 379 ident: bib40 article-title: Radiotherapy and immunotherapy: a beneficial liaison? publication-title: Nat. Rev. Clin. Oncol. – volume: 16 start-page: 834 issue: 1 year: 2016 ident: 10.1016/j.suronc.2019.01.006_bib15 article-title: Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm publication-title: BMC Canc. doi: 10.1186/s12885-016-2894-9 – volume: 14 start-page: 365 issue: 6 year: 2017 ident: 10.1016/j.suronc.2019.01.006_bib40 article-title: Radiotherapy and immunotherapy: a beneficial liaison? publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2016.211 – volume: 30 start-page: 61 issue: 1 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib23 article-title: Current strategy for staging and treatment: the BCLC update and future prospects publication-title: Semin. Liver Dis. doi: 10.1055/s-0030-1247133 – volume: 8 issue: 8 year: 2013 ident: 10.1016/j.suronc.2019.01.006_bib35 article-title: Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome publication-title: PLoS One doi: 10.1371/journal.pone.0072306 – volume: 17 start-page: 140 issue: 2 year: 2015 ident: 10.1016/j.suronc.2019.01.006_bib14 article-title: Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of >/= 3 cm publication-title: HPB (Oxford) doi: 10.1111/hpb.12331 – volume: 389 start-page: 2492 issue: 10088 year: 2017 ident: 10.1016/j.suronc.2019.01.006_bib37 article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial publication-title: Lancet doi: 10.1016/S0140-6736(17)31046-2 – volume: 15 start-page: 279 issue: 4 year: 2005 ident: 10.1016/j.suronc.2019.01.006_bib32 article-title: Partial volume tolerance of the liver to radiation publication-title: Semin. Radiat. Oncol. doi: 10.1016/j.semradonc.2005.04.005 – volume: 149 start-page: 7 issue: 1 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib20 article-title: Propensity score methods publication-title: Am. J. Ophthalmol. doi: 10.1016/j.ajo.2009.08.024 – volume: 33 start-page: 41 issue: 1 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib7 article-title: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study publication-title: Cardiovasc. Interv. Radiol. doi: 10.1007/s00270-009-9711-7 – volume: 37 start-page: 429 issue: 2 year: 2003 ident: 10.1016/j.suronc.2019.01.006_bib27 article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival publication-title: Hepatology doi: 10.1053/jhep.2003.50047 – volume: 160 start-page: 1425 issue: 6 year: 2016 ident: 10.1016/j.suronc.2019.01.006_bib21 article-title: Propensity scores for comparative effectiveness research: finding the right match publication-title: Surgery doi: 10.1016/j.surg.2016.05.045 – volume: 59 start-page: 81 issue: 1 year: 2013 ident: 10.1016/j.suronc.2019.01.006_bib39 article-title: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C publication-title: J. Hepatol. doi: 10.1016/j.jhep.2013.02.022 – volume: 359 start-page: 1734 issue: 9319 year: 2002 ident: 10.1016/j.suronc.2019.01.006_bib5 article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08649-X – volume: 12 start-page: 218 issue: 3 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib10 article-title: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma publication-title: Clin. Transl. Oncol. doi: 10.1007/s12094-010-0492-x – volume: 31 start-page: 1631 issue: 13 year: 2013 ident: 10.1016/j.suronc.2019.01.006_bib13 article-title: Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.44.1659 – volume: 4 start-page: 439 issue: 2 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib25 article-title: Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma publication-title: Hepatol. Int. doi: 10.1007/s12072-010-9165-7 – volume: 11 start-page: 525 issue: 9 year: 2014 ident: 10.1016/j.suronc.2019.01.006_bib43 article-title: Treatment of intermediate-stage hepatocellular carcinoma publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2014.122 – volume: 40 start-page: i19 issue: Suppl 1 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib2 article-title: Liver cancer working group report publication-title: Jpn. J. Clin. Oncol. doi: 10.1093/jjco/hyq123 – volume: 53 start-page: 1020 issue: 3 year: 2011 ident: 10.1016/j.suronc.2019.01.006_bib18 article-title: American association for the study of liver diseases. Management of hepatocellular carcinoma: an update publication-title: Hepatology doi: 10.1002/hep.24199 – volume: 81 start-page: e447 issue: 4 year: 2011 ident: 10.1016/j.suronc.2019.01.006_bib11 article-title: Stereotactic body radiotherapy for primary hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2011.04.011 – volume: 30 start-page: 52 issue: 1 year: 2010 ident: 10.1016/j.suronc.2019.01.006_bib19 article-title: Modified RECIST(mRECIST) assessment for hepatocellular carcinoma publication-title: Semin. Liver Dis. doi: 10.1055/s-0030-1247132 – volume: 62 start-page: 1371 issue: 5 year: 2005 ident: 10.1016/j.suronc.2019.01.006_bib30 article-title: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2005.01.002 – volume: 57 start-page: 113 issue: 1 year: 2003 ident: 10.1016/j.suronc.2019.01.006_bib33 article-title: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/S0360-3016(03)00434-6 – volume: 97 start-page: 939 issue: 5 year: 2017 ident: 10.1016/j.suronc.2019.01.006_bib31 article-title: Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2017.01.221 – volume: 100 start-page: 122 issue: 1 year: 2018 ident: 10.1016/j.suronc.2019.01.006_bib22 article-title: Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2017.09.001 – volume: 29 start-page: 339 issue: 3 year: 2011 ident: 10.1016/j.suronc.2019.01.006_bib24 article-title: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version publication-title: Dig. Dis. doi: 10.1159/000327577 – volume: 15 start-page: 563 issue: 5 year: 2017 ident: 10.1016/j.suronc.2019.01.006_bib26 article-title: NCCN guidelines insights: hepatobiliary cancers, version 1.2017 publication-title: J. Natl. Compr. Canc. Netw. : JNCCN doi: 10.6004/jnccn.2017.0059 – volume: 36 start-page: 1611 issue: 16 year: 2018 ident: 10.1016/j.suronc.2019.01.006_bib41 article-title: Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.2229 – volume: 34 start-page: 174 issue: 2 year: 2014 ident: 10.1016/j.suronc.2019.01.006_bib6 article-title: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel publication-title: Liver Int. : Offic. J. Int. Assoc. Stud. Liver doi: 10.1111/liv.12314 – volume: 192 start-page: 92 issue: 2 year: 2016 ident: 10.1016/j.suronc.2019.01.006_bib17 article-title: Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas publication-title: Strahlenther. Onkol. : Organ der Deutschen Rontgengesellschaft [et al] doi: 10.1007/s00066-015-0929-9 – volume: 19 start-page: 940 issue: 7 year: 2018 ident: 10.1016/j.suronc.2019.01.006_bib38 article-title: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30351-6 – ident: 10.1016/j.suronc.2019.01.006_bib42 – volume: 2 start-page: 16018 year: 2016 ident: 10.1016/j.suronc.2019.01.006_bib1 article-title: Hepatocellular carcinoma publication-title: Nat. Rev. Dis. Prim. doi: 10.1038/nrdp.2016.18 – year: 2016 ident: 10.1016/j.suronc.2019.01.006_bib8 – volume: 57 start-page: 113 issue: 1 year: 2003 ident: 10.1016/j.suronc.2019.01.006_bib9 article-title: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/S0360-3016(03)00434-6 – volume: 118 start-page: 5424 issue: 21 year: 2012 ident: 10.1016/j.suronc.2019.01.006_bib12 article-title: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization publication-title: Cancer doi: 10.1002/cncr.27533 – volume: 25 start-page: 1189 issue: 6 year: 2005 ident: 10.1016/j.suronc.2019.01.006_bib28 article-title: Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma publication-title: Liver Int. : Offic. J. Int. Assoc. Stud. Liver doi: 10.1111/j.1478-3231.2005.01170.x – volume: 115 start-page: 591 issue: 5 year: 2017 ident: 10.1016/j.suronc.2019.01.006_bib3 article-title: Global trends in the burden of liver cancer publication-title: J. Surg. Oncol. doi: 10.1002/jso.24518 – volume: 35 start-page: 1164 issue: 5 year: 2002 ident: 10.1016/j.suronc.2019.01.006_bib4 article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma publication-title: Hepatology doi: 10.1053/jhep.2002.33156 – volume: 253 start-page: 745 issue: 4 year: 2011 ident: 10.1016/j.suronc.2019.01.006_bib34 article-title: Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience publication-title: Ann. Surg. doi: 10.1097/SLA.0b013e3182111195 – volume: 122 start-page: 2041 issue: 13 year: 2016 ident: 10.1016/j.suronc.2019.01.006_bib16 article-title: Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation publication-title: Cancer doi: 10.1002/cncr.30008 – volume: 93 start-page: E169 issue: 3, Supplement year: 2015 ident: 10.1016/j.suronc.2019.01.006_bib29 article-title: Potential benefits of fractionation over SBRT for large liver tumors publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2015.07.984 – volume: 18 start-page: 905 issue: 8 year: 2018 ident: 10.1016/j.suronc.2019.01.006_bib36 article-title: Recent developments with immunotherapy for hepatocellular carcinoma publication-title: Expert Opin. Biol. Ther. doi: 10.1080/14712598.2018.1499722 |
| SSID | ssj0006721 |
| Score | 2.33074 |
| Snippet | This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation... BackgroundThis study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 228 |
| SubjectTerms | Abdomen Demographics Demography Disease Disease control Hepatitis Hepatocellular carcinoma Hospitals Liver cancer Matching Medical prognosis Metastasis Multivariate analysis Outcomes Patients Radiation Radiation therapy Stereotactic body radiation therapy Survival Toxicity Transarterial chemoembolization Tumors Unresectable |
| Title | Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0960740418303839 https://dx.doi.org/10.1016/j.suronc.2019.01.006 https://www.ncbi.nlm.nih.gov/pubmed/30851906 https://www.proquest.com/docview/2308519438 https://www.proquest.com/docview/2190099619 |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELamISFeEL_pNqZD4jU0TZw65q1MTAW0vcCkvVm2Y4uiNa7alGkv_FH8hdw5ThESaIjHpL7UyV3uPsd33zH2qvHOF04WmWxwpcOtdJmshMvqiroba4FmQN8hz86n8wv-4bK63GMnQy0MpVUm39_79Oit05lxeprj1WIx_kTgW_Cco1HmuM6iIj7OBfHnv_7-K81jKmLtFQ3OaPRQPhdzvDbbdWiJyHAiI3kn9T36c3j6G_yMYej0Abuf8CPM-ik-ZHuufcTunqUd8sfsx9tYnwP4n98WaEUQm4AD0SG40MWKKDChuYE1kRKQVqAvwboBjyYRrjGUQRebiFOyJ1onoFqXwS1NuEo1m7BooQ2RJ8h2VHoFXzCodYE2ASirFSw1KGrDUr-BGazoc39LqR-wIc5MQIyMl2xAJz6UJ-zi9N3nk3mW-jJkFuFFlzVTzSvrtdcGTaCsC1sKPOBCWkkLHisKTzu6WtS-QJciq6KujfD1hHva1yufsn2cpXvOgFthtDbeCFvzaoJRwKC0Ex5hVu4LP2LloA5lE2k59c64UkN22lfVK1GRElU-UajEEct2UquetOOW8dWgaTUUpKILVRhVbpETO7nfjPYfJI8Gg1LJaWwUPhrEv5KX9Yi93P2MrzupT7cubHEMAjgE9bjsHbFnvSHubrEXz6cH_z2tQ3aPjvocuyO236237gWCrs4cx7fqmN2Zvf84P_8JsugyZw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbGJgEviN8UBhwSr1HbxKlj3srE1LG1L2zS3izHsUXRGldtyrR_a38hd44TCQk0xGMTX-rkvtyd47vvGPtYOetSK9NEVrjS4UbaRObCJkVO3Y21QBjQd8j5YjK74F8v88s9dtTVwlBaZbT9rU0P1joeGcanOVwvl8NvFHwLPuIIyhGus-Q9dkDsVAj2g-nJ6WzRG-SJCOVXND4hga6CLqR5bXcbXxOX4VgG_k5qffRnD_W3CDR4ouPH7FEMIWHazvIJ27P1U3Z_HjfJn7Hbz6FEB_A_fy4RSBD6gAMxIljfhKIoKH11AxviJSDFQFuFdQMOUeGv0ZtBE_qIU74nAhRQsytvV6W_imWbsKyh9oEqyDRUfQXf0a81nvYBKLEVDPUoqv1Kf4IprOmLf03ZH7Al2kzAMBkvWYGOlCjP2cXxl_OjWRJbMyQGI4wmqSaa58Zpp0tEQVakJhP4gwtpJK15jEgdbepqUbgUrYrM06IohSvG3NHWXvaC7eMs7SsG3IhS69KVwhQ8H6MjKFHaCoeR1silbsCyTh3KRN5yap9xpboEtR-qVaIiJarRWKESByzppdYtb8cd4_NO06qrSUUrqtCx3CEnernfcPsPkocdoFS0G1uFjwZDYMmzYsA-9KfxjSf16dr6HY7BGA7jelz5DtjLFoj9Lbbio8nr_57We_Zgdj4_U2cni9M37CGdaVPuDtl-s9nZtxiDNeW7-I79AgX5NRg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Better+survival+after+stereotactic+body+radiation+therapy+following+transarterial+chemoembolization+in+nonresectable+hepatocellular+carcinoma%3A+A+propensity+score+matched+analysis&rft.jtitle=Surgical+oncology&rft.au=Wong%2C+Tiffany+CL&rft.au=Chi-Leung%2C+Chiang&rft.au=Ann-Shing%2C+Lee&rft.au=Lee%2C+Victor+HF&rft.date=2019-03-01&rft.pub=Elsevier+Limited&rft.issn=0960-7404&rft.eissn=1879-3320&rft.volume=28&rft.spage=228&rft_id=info:doi/10.1016%2Fj.suronc.2019.01.006&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-7404&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-7404&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-7404&client=summon |